會議議程

Executive Summary：
Dr. Chen graduated from Taipei Medical University and completed his neurological residency training at National Taiwan University Hospital in Taipei. Since 2012, he has served as an attending physician and movement disorder specialist in the Department of Neurology at National Taiwan University Hospital Hsinchu Branch.

Dr. Chen acquired expertise in microelectrode recording and clinical deep brain stimulation (DBS) techniques under the guidance of Dr. Chun-Hwei Tai at National Taiwan University Hospital (NTUH) and established DBS system of NTUH Hsinchu in 2015. In the field of non-invasive neurostimulation, he has conducted extensive research on transcranial magnetic stimulation (TMS) and patterned repetitive TMS (rTMS) in collaboration with Professor Ying-Zu Huang from 2016. In addition to his clinical expertise, Dr. Chen pursued a research fellowship in Professor Robert Chen’s lab at the Krembil Brain Institute, University of Toronto from 2018 to 2019. His primary research interests focus on neuromodulation and electrophysiological assessment of movement disorders, utilizing techniques such as DBS, TMS, and low-intensity transcranial focused ultrasound (TUS). Additionally, he has explored the cortical plasticity effects of TUS and developed a novel patterned repetitive TUS protocol in collaboration with Professor Robert Chen.
In 2020, Dr. Chen established his clinical neurophysiology lab, integrating electrophysiological assessments with advanced equipment, including multi-channel EMG, EEG, single/paired TMS, rTMS, evoked potentials, and gait analysis. His research encompasses a broad spectrum of movement disorders, such as parkinsonism, tremor, dystonia, functional movement disorders, and gait abnormalities.
Dr. Chen has published numerous influential articles on the principles of electrophysiology in movement disorders and human cortical physiological function. He currently serves as the Deputy Director of the Department of Neurology at National Taiwan University Hospital Hsinchu Branch.

Lecture Abstract：
Atypical parkinsonian syndromes (APs) encompassing conditions such as progressive supranuclear palsy, multiple system atrophy, corticobasal syndrome, dementia with Lewy bodies, and frontotemporal dementia present a formidable clinical challenge due to their overlapping motor and non-motor manifestations. Differentiating among these various APs is difficult, as clinicians often must rely on the delayed emergence of characteristic clinical signs for a definitive diagnosis. While advanced imaging and fluid biomarkers hold diagnostic promise, their utility is frequently limited by inconsistent findings or restricted availability in daily practice. Consequently, neurophysiological assessments including surface electromyography (EMG), transcranial magnetic stimulation (TMS), polysomnography, brainstem reflexes, and kinematic measures provide highly accessible and practical diagnostic alternatives. These techniques are crucial for unraveling the distinct pathophysiological mechanisms and evaluating the specific impaired neural circuits underlying different APs. This presentation will review the unique neurophysiological characteristics of various APs, evaluating their role in both research contexts and clinical applications. Ultimately, we will propose a practical, stepwise approach based on the sequential application of specific neurophysiological techniques to facilitate early and accurate differential diagnosis among atypical parkinsonian syndromes.

Executive Summary：
Dr. Chiang was trained at Chang Gung Memorial Hospital, Linkou branch. She became an attending neurologist in the Neurology Department of Taipei Tzu Chi General Hospital and later changed gears to Taipei Veterans General Hospital in 2018. She was trained as a movement disorders clinical fellow in the Movement Disorder Unit of Westmead Hospital, Australia, with Prof. Victor Fung from 2014 to 2015.

Lecture Abstract：
Atypical parkinsonian syndromes, including progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal syndrome (CBS), and dementia with Lewy bodies (DLB), are frequently misdiagnosed as Parkinson’s disease (PD), especially in the early stages. Accurate application of clinical diagnostic criteria is essential to distinguish these entities, guide prognosis, and optimize management. This presentation provides an overview of the current diagnostic frameworks, including the Movement Disorder Society criteria for PSP and MSA and consensus guidelines for CBS and DLB. Key clinical features, supportive findings, and exclusionary signs will be highlighted, together with the role of neuroimaging and ancillary testing in increasing diagnostic certainty. Case-based discussions will illustrate typical presentations and diagnostic pitfalls encountered in real-world practice.

Executive Summary：
Huw Morris is Professor of Neurology and Neurogenetics, at UCL Queen Square Institute of Neurology, and Honorary Consultant Neurologist at the Royal Free Hospital and the National Hospital, Queen Square, London. His clinical and research training took place at the National Hospital Queen Square, the Mayo Clinic and the Western Pacific island of Guam. He began research in PSP and related disorders as a PSP Association and MRC Clinical Research Fellow in 1997. His main interests are Neurogenetics, Movement Disorders and Dementia. He leads a UK-wide research network in PSP, Corticobasal syndrome and MSA (PROSPECT and EXPRESS) and a UK-wide research project in genetic Parkinson’s (Parkinson’s Families Project). He leads the cohort group for Parkinson’s and Parkinson’s Plus of the Global Parkinson’s Genetics Program (gp2.org). He also studies genetic determinants of progression and variation in Parkinsonian disorders using clinical and brain bank analysis to help to define new treatments.

Lecture Abstract：
We have made major advances in the understanding the genetics familial and sporadic and sporadic Parkinson's. This process has been accelerated by the Global Parkinson's Genetics Program (gp2.org) and the focus on non-European populations. Our challenge now is to convert this into new disease modifying therapies and to use this information to understand disease heterogeneity and disease mechanisms as part of global collaborative efforts. One important aspect of this is to integrate pathology and biomarker data into this effort to define new insights. I will define current progress, recent discoveries and the road ahead over the next 5 years.